Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Mogroside V attenuates gestational diabetes mellitus via SIRT1 pathway in a rat model

Teng Zhou^1,2, Xiaodong Fu¹, Hongyi Li³, Yan Yin⁴

¹Department of Gynaecology and Obstetrics, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China; ²Department of Gynaecology and Obstetrics, Neijiang City Maternal and Child Health Care Hospital, Neijiang City, Sichuan 641000, China; ³Department of Urinary Surgery, Neijiang Shizhong District People's Hospital, Neijiang City, Sichuan 641100, China; ⁴Department of Pharmacy, Shaoxing TCM Hospital Affiliated to Zhejiang Chinese Medical University, Shaoxing, Zhejiang 312000, China.

For correspondence:- Yan Yin Email: yin_yan1@163.com Tel:+8657589102212

Accepted: 14 November 2021 Published: 30 December 2021

Citation: Zhou T, Fu X, Li H, Yin Y. Mogroside V attenuates gestational diabetes mellitus via SIRT1 pathway in a rat model. Trop J Pharm Res 2021; 20(12):2533-2538 doi: 10.4314/tjpr.v20i12.11

© 2021 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the function of mogroside V in gestational diabetes mellitus in a rat model.

Methods: Rats were divided into three groups: control rats (N = 6), rats with gestational diabetes mellitus (N = 6), and mogroside V-treated rats with gestational diabetes mellitus (GDM, N = 6). Rats in the gestational diabetes mellitus group were injected intraperitoneally with 35 mg/kg streptozotocin while rats in mogroside V group were orally gavaged with 100 mg/kg mogroside V for 20 days. Blood sugar, insulin, and leptin levels were measured using commercial kits. Triglyceride (TG), total cholesterol (TC), and high-density lipoprotein (HDL) levels were also assessed using commercial kits. Hematoxylin-eosin staining was used to determine morphological changes in placenta and pancreas.

Results: Streptozotocin injection significantly increased blood sugar, insulin, and leptin levels and elevated the body weight of both fetal and gestational diabetes mellitus rats (p < 0.01). The serum levels of TG, TC and HDL also increased in rats with gestational diabetes mellitus. However, mogroside V treatment reduced blood sugar, insulin, and leptin levels, and lowered the serum levels of TG, TC and HDL. Streptozotocin injection induced morphological damage in placenta and pancreas, but mogroside V administration ameliorated the pathologic damage. Additionally, mogroside V administration attenuated the streptozotocin injection-induced decrease in SIRT1 levels in the rats.

Conclusion: Mogroside V alleviates pathological damage in the placenta and pancreas of rats with gestational diabetes mellitus by down-regulating SIRT1, indicating the potential of mogroside V for managing gestational diabetes mellitus.

Keywords: Mogroside V, Placenta, Pancreas, Gestational diabetes mellitus, SIRT1